Information Provided By:
Fly News Breaks for December 18, 2019
Dec 18, 2019 | 07:02 EDT
Citi analyst Joel Beatty believes Esperion Therapeutics' bempedoic acid is likely to be approved in Q1 of 2020 and that the shares should trade to $79 on the news. Bempedoic Acid is likely to be approved in both the U.S. and Europe, Beatty tells investors in a research note. The analyst maintains a Buy rating on Esperion shares with a $73 price target.
News For ESPR From the Last 2 Days
There are no results for your query ESPR